secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2024-01-18T23:59:59+00:00
Accession:  0001171843-24-000297
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst adopts amended By-Laws for DGCL compliance and universal proxy card rules
--------------------------------------------------------------------------------

- Updates to align with DGCL Sections 219 and 222 regarding stockholder list and meeting adjournment.
- Revisions to stockholder nomination procedures to comply with universal proxy card rules (Rule 14a-19).
- Limits stockholder nominee count to number of directors to be elected; clarifies timing for substitute nominations.
- Requires soliciting stockholders to use a proxy card color other than white.
- Technical and administrative changes also adopted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184324000297/0001171843-24-000297-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184324000297/f8k_011824.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-000297

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer